N-[2-(2,3-dihydro-1,4-benzodioxin-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-4,5-dimethyl-1H-pyrazole-3-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并二恶烷
• 英文名称: N-[2-(2,3-dihydro-1,4-benzodioxin-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-4,5-dimethyl-1H-pyrazole-3-carboxamide
• 化学式: C₂₁H₁₉N₅O₃
• 分子量: 389.4
• InChiKey: CYNFIHOZNXFMAE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  29
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  105
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR
  申请人：Plexxikon Inc.

  公开号：US20140213554A1

  公开（公告）日：2014-07-31

  Compounds active on c-kit protein kinases or mutant c-kit protein kinases having any mutations are described, as well as methods of making and using such compounds to treat diseases and conditions associated with aberrant activity of the c-kit protein kinases and/or mutant c-kit protein kinases.

  本文介绍了对c-kit蛋白激酶或带有任何突变的突变c-kit蛋白激酶活性的化合物，以及制备和使用这些化合物治疗与c-kit蛋白激酶和/或突变c-kit蛋白激酶的异常活性相关的疾病和病状的方法。
• Compounds and methods for kinase modulation, and indications therefor
  申请人：Plexxikon Inc.

  公开号：US10301280B2

  公开（公告）日：2019-05-28

  Compounds active on c-kit protein kinases or mutant c-kit protein kinases having any mutations are described, as well as methods of making and using such compounds to treat diseases and conditions associated with aberrant activity of the c-kit protein kinases and/or mutant c-kit protein kinases.

  本文描述了对具有任何突变的 c-kit 蛋白激酶或突变 c-kit 蛋白激酶具有活性的化合物，以及制造和使用此类化合物治疗与 c-kit 蛋白激酶和/或突变 c-kit 蛋白激酶活性异常有关的疾病和病症的方法。
• US9676748B2
  申请人：——

  公开号：US9676748B2

  公开（公告）日：2017-06-13
• [EN] COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR<br/>[FR] COMPOSÉS ET PROCÉDÉS POUR LA MODULATION DE KINASE, ET INDICATIONS ASSOCIÉES
  申请人：PLEXXIKON INC

  公开号：WO2014100620A2

  公开（公告）日：2014-06-26

  Compounds active on c-kit protein kinases or mutant c-kit protein kinases having any mutations are described, as well as methods of making and using such compounds to treat diseases and conditions associated with aberrant activity of the c-kit protein kinases and/or mutant c-kit protein kinases.